Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,348 matching trials from the live ClinicalTrials.gov search.
Filters: New Haven, Connecticut Clear all
Recruiting Not applicable Interventional

Exercise Intervention and Immunodeficiency

NCT07698197
View directory record Official record
Conditions
Primary Antibody Deficiency Disorders
Interventions
App-based exercise intervention
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Milford, Connecticut • North Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 30, 2026, 4:23 PM EDT
Completed Not applicable Interventional

Feasibility and Efficacy of a Digital Neurotherapy Protocol for Management of Depression, Cognition, and Quality of Life in Cancer Survivors

NCT04961047
View directory record Official record
Conditions
Depression, Cognition, Quality of Life
Interventions
Digital neurotherapy (DNT) Treatment, Wait list control group
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 30, 2026, 4:23 PM EDT
Completed No phase listed Observational

Creation of a Digital Heart Failure Registry Using a Novel Mobile Health Platform: HUGO-HF

NCT03810638
View directory record Official record
Conditions
Heart Failure
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Oct 30, 2026, 4:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn if the Study Medicine Called Carbamazepine Changes How the Body Processes PF-07220060

NCT06897683
View directory record Official record
Conditions
Healthy Adults
Interventions
PF-07220060, Carbamazepine ER Tablet
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 30, 2026, 4:23 PM EDT
Completed Phase 3 Interventional Results available

Heart And Lung Failure - Pediatric INsulin Titration Trial

NCT01565941
View directory record Official record
Conditions
Heart Failure, Respiratory Failure
Interventions
Insulin
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Weeks to 17 Years
Enrollment
713 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
33
States / cities
Long Beach, California • Los Angeles, California • Oakland, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Oct 30, 2026, 4:23 PM EDT
Active, not recruiting Phase 1 Interventional

Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer

NCT02503722
View directory record Official record
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Laboratory Biomarker Analysis, Osimertinib, Pharmacological Study, Sapanisertib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
3
States / cities
New Haven, Connecticut • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 30, 2026, 4:23 PM EDT
Active, not recruiting Phase 2 Interventional

A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

NCT06614192
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Telisotuzumab Adizutecan
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
24
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 30, 2026, 4:23 PM EDT
Terminated Phase 2 Interventional Results available

Ketamine in Borderline Personality Disorder

NCT03395314
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 60 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 30, 2026, 4:23 PM EDT
Recruiting Phase 2Phase 3 Interventional

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

NCT05058651
View directory record Official record
Conditions
Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma, Recurrent Extrapulmonary Neuroendocrine Carcinoma, Unresectable Extrapulmonary Neuroendocrine Carcinoma
Interventions
Atezolizumab, Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Etoposide, Magnetic Resonance Imaging, Patient Observation
Biological · Procedure · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
265
States / cities
Anchorage, Alaska • Phoenix, Arizona • Anaheim, California + 199 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 4:23 PM EDT
Completed No phase listed Observational Results available

Screening for Cardiac Amyloidosis With Nuclear Imaging for Minority Populations

NCT03812172
View directory record Official record
Conditions
Amyloid Cardiomyopathy, Transthyretin-Related
Interventions
99mTc-PYP or 99m Tc-HDP
Drug
Lead sponsor
Mathew S. Maurer, MD
Other
Eligibility
60 Years and older
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
New Haven, Connecticut • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 30, 2026, 4:23 PM EDT
Recruiting Phase 1 Interventional

SNV1521 in Participants With Advanced Solid Tumors

NCT06220864
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
SNV1521, DB-1310, Abiraterone, Darolutamide
Drug
Lead sponsor
ParVation Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
New Haven, Connecticut • Philadelphia, Pennsylvania • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 30, 2026, 4:23 PM EDT
Completed Phase 3 Interventional Results available

IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.

NCT00091507
View directory record Official record
Conditions
Angina, Unstable, Cardiovascular Diseases, Heart Diseases, Coronary Disease, Myocardial Infarction, Heart Failure, Congestive
Interventions
GIK, Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
30 Years and older
Enrollment
911 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
13
States / cities
Anchorage, Alaska • New Haven, Connecticut • Macon, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Oct 30, 2026, 4:23 PM EDT
Completed Phase 2 Interventional Results available

Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Chronic Low Back Pain

NCT04874636
View directory record Official record
Conditions
Chronic Low-back Pain
Interventions
LY3556050, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
33
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 30, 2026, 4:23 PM EDT
Terminated Phase 3 Interventional

Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE)

NCT01449292
View directory record Official record
Conditions
Pulmonary Emphysema
Interventions
Treatment plus Optimal Medical Therapy, Optimal Medical Therapy
Device · Other
Lead sponsor
Aeris Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Oct 30, 2026, 4:23 PM EDT
Completed Not applicable Interventional

Tka Assay for CDK4/6i

NCT06572800
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma
Interventions
DiviTum-TKa
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
18
States / cities
Derby, Connecticut • Fairfield, Connecticut • Glastonbury, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 30, 2026, 4:23 PM EDT
Completed Phase 4 Interventional Results available

Counseling for Primary Care Office-based Buprenorphine

NCT00595764
View directory record Official record
Conditions
Opiate Dependence
Interventions
Manual-guided Physician Management (PM), Physician Management (PM) combined with on-site manual-guided Cognitive Behavioral Therapy (CBT)
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 30, 2026, 4:23 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Long-term Safety of VX-445 Combination Therapy

NCT04043806
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
ELX/TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
46
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Oct 30, 2026, 4:23 PM EDT
Terminated Phase 3 Interventional Results available

PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban

NCT04142658
View directory record Official record
Conditions
Aortic Valve Disease, Aortic Valve Stenosis, Aortic Valve Failure
Interventions
Apixaban 5 MG, Apixaban 2.5 MG, Warfarin, On-X Aortic Mechanical Valve
Drug · Device
Lead sponsor
Artivion Inc.
Industry
Eligibility
18 Years and older
Enrollment
863 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
62
States / cities
Tucson, Arizona • Little Rock, Arkansas • Loma Linda, California + 50 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 30, 2026, 4:23 PM EDT
Terminated Phase 3 Interventional Results available

Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

NCT02927249
View directory record Official record
Conditions
Node Positive HER2 Negative Breast Cancer
Interventions
Placebo, Aspirin
Other · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 69 Years
Enrollment
3,021 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1426
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 902 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 30, 2026, 4:23 PM EDT
Completed Phase 3 Interventional Results available

Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation

NCT00412984
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
warfarin, apixaban
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Not listed
Enrollment
20,976 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
284
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 206 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 30, 2026, 4:23 PM EDT
Completed Phase 3 Interventional Results available

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

NCT03740165
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
Interventions
Pembrolizumab, Placebo for pembrolizumab, Carboplatin, Paclitaxel, Olaparib, Placebo for olaparib, Bevacizumab, Docetaxel
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
43
States / cities
Birmingham, Alabama • Tucson, Arizona • Burbank, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 30, 2026, 4:23 PM EDT
Completed No phase listed Observational

Defining Exercise Hemodynamics and Function After Transcatheter Aortic Valve Replacement (DEFINE-TAVR) Study.

NCT05567809
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Timeline
2022 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 30, 2026, 4:23 PM EDT
Recruiting Not applicable Interventional

Skin Color Matching in Head and Neck Reconstructive Surgery

NCT07431099
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Trauma
Interventions
RECELL® Autologous Cell Harvesting Device
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Guilford, Connecticut • Milford, Connecticut • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 30, 2026, 4:23 PM EDT
Recruiting Phase 3 Interventional

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

NCT07166406
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
Interventions
Atezolizumab, Bevacizumab, Biospecimen Collection, Computed Tomography, Durvalumab, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy, Tremelimumab
Biological · Procedure · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
138
States / cities
Berkeley, California • Cameron Park, California • Fremont, California + 108 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 30, 2026, 4:23 PM EDT